TAYLOR GLEN A
10% owner
- Shares
- 18,750,000
- Price
- $0.40
- Value
- $7,500,000
COCH
No net buyers or sellers account for the net balance. There is no cluster of three distinct buyers within 30 days. We found 6 CEO/CFO purchases over 12 months.
Only open-market P purchases and S sales count toward the signal. Vesting, options, taxes and gifts remain in the source data but do not trigger alerts. Rule 10b5-1 trades are shown as informational.
3-month balance
$0.00
0 buyers · 0 sellers
12-month purchases
$8,173,460
6 distinct insiders
12-month sales
$0.00
0 distinct insiders
Highlighted alerts
18
0 Rule 10b5-1 trades treated as informational
Buying cluster · 30 days
Fewer than three distinct buyers
CEO/CFO purchases · 12 months
6 executive purchases found
The same filtered trades as JSON for your scripts, alerts or AI agent, for 5,500+ US companies — plus sentiment, news, financials and breakout setups. Free · every API · 1,000 requests a month · no card required.
COCH overview: breakout setup, X sentiment and insiders in one page →
The SEC XML stores every transaction. Raspberry keeps that evidence, reads the footnotes and separates voluntary open-market activity from vesting, option exercises, gifts, tax withholding, stock purchase and dividend reinvestment plans and pre-programmed 10b5-1 trades.
Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months. Options to purchase 62,500 shares vest on 8/24/2027, and 187,500 shares vest pro rata on the 24th of each month thereafter for 36 consecutive months. Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.
Voluntary purchases and sales; administrative noise stays hidden.
TAYLOR GLEN A
10% owner
TAYLOR GLEN A
10% owner
TAYLOR GLEN A
10% owner
Patel Mona Chetan
Director
Patel Mona Chetan
Director
Patel Mona Chetan
Director
Potashnick Robert
Interim CFO
Potashnick Robert
Interim CFO
Potashnick Robert
Interim CFO
Kantor Susan
Director
Kantor Susan
Director
Kantor Susan
Director
BRYNELSEN CHARLES
Director
BRYNELSEN CHARLES
Director
BRYNELSEN CHARLES
Director
Lucas Brent T.
Chief Executive Officer
Lucas Brent T.
Chief Executive Officer
Lucas Brent T.
Chief Executive Officer
| Date | Insider | Transaction | Shares | Price | Value | Reading |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | TAYLOR GLEN A 10% owner | Purchase | 18,750,000 | $0.40 | $7,500,000 | |
| Feb 12, 2026 | TAYLOR GLEN A 10% owner | Purchase | 18,750,000 | $0.00 | $0.00 | |
| Feb 12, 2026 | TAYLOR GLEN A 10% owner | Purchase | 11,250,000 | $0.00 | $0.00 | |
| Feb 12, 2026 | Patel Mona Chetan Director | Purchase | 312,500 | $0.40 | $125,000 | |
| Feb 12, 2026 | Patel Mona Chetan Director | Purchase | 312,500 | $0.00 | $0.00 | |
| Feb 12, 2026 | Patel Mona Chetan Director | Purchase | 187,500 | $0.00 | $0.00 | |
| Feb 12, 2026 | Potashnick Robert Interim CFO | Purchase | 212,500 | $0.40 | $85,000 | |
| Feb 12, 2026 | Potashnick Robert Interim CFO | Purchase | 212,500 | $0.00 | $0.00 | |
| Feb 12, 2026 | Potashnick Robert Interim CFO | Purchase | 127,500 | $0.00 | $0.00 | |
| Feb 12, 2026 | Kantor Susan Director | Purchase | 96,150 | $0.40 | $38,460 | |
| Feb 12, 2026 | Kantor Susan Director | Purchase | 96,150 | $0.00 | $0.00 | |
| Feb 12, 2026 | Kantor Susan Director | Purchase | 57,690 | $0.00 | $0.00 | |
| Feb 12, 2026 | BRYNELSEN CHARLES Director | Purchase | 1,000,000 | $0.40 | $400,000 | |
| Feb 12, 2026 | BRYNELSEN CHARLES Director | Purchase | 1,000,000 | $0.00 | $0.00 | |
| Feb 12, 2026 | BRYNELSEN CHARLES Director | Purchase | 600,000 | $0.00 | $0.00 | |
| Feb 12, 2026 | Lucas Brent T. Chief Executive Officer | Purchase | 62,500 | $0.40 | $25,000 | |
| Feb 12, 2026 | Lucas Brent T. Chief Executive Officer | Purchase | 62,500 | $0.00 | $0.00 | |
| Feb 12, 2026 | Lucas Brent T. Chief Executive Officer | Purchase | 37,500 | $0.00 | $0.00 |
“Alert” means a voluntary, unscheduled transaction according to the filing; it is not an investment recommendation. Official source: SEC EDGAR.